Retatrutide Protocol (24 weeks)
Investigational triple-agonist (GLP-1/GIP/glucagon) Phase 2 trial titration: 2 → 4 → 8 → 12 mg weekly, escalating every 4 weeks to the 12mg maintenance dose.
Concentration over time
| Date | Retatrutide |
|---|---|
| W1 | 0.00 |
| W3 | 4901.63 |
| W5 | 5910.50 |
| W7 | 11019.78 |
| W9 | 12071.38 |
| W11 | 22091.09 |
| W13 | 24152.80 |
| W15 | 34380.15 |
| W17 | 36485.73 |
| W19 | 36918.61 |
| W21 | 37007.71 |
| W23 | 37026.33 |
| W25 | 37029.95 |
Protocol summary
Retatrutide Protocol (24 weeks) · 24 weeks starting Jul 20, 26
- Retatrutide — 2.00 mg Every 7 days, weeks 0–3
- Retatrutide — 4.00 mg Every 7 days, weeks 4–7
- Retatrutide — 8.00 mg Every 7 days, weeks 8–11
- Retatrutide — 12.0 mg Every 7 days, weeks 12–24
Protocol overview
- Category
- weightloss
- Duration
- 24 weeks
- Compounds
- 4
- Tags
- glp-1, gip, glucagon, investigational, retatrutide
Compounds in this protocol
- Retatrutide 2mg — 2 mg, every-7-days (weeks 0-3)
- Retatrutide 4mg — 4 mg, every-7-days (weeks 4-7)
- Retatrutide 8mg — 8 mg, every-7-days (weeks 8-11)
- Retatrutide 12mg — 12 mg, every-7-days (weeks 12-24)
How to read this protocol
The chart above shows the modeled blood concentration of each compound over the 24-week duration. Each compound accumulates toward steady state (roughly 5 half-lives). The peak-to-trough ratio within each dose interval depends on the injection frequency relative to the half-life.
Use the [peak-trough estimator](/tools/peak-trough) to see predicted levels at any point, or the [clearance calculator](/tools/clearance) to estimate washout after the protocol ends. The [PCT planner](/pct-planner) estimates when to start post-cycle therapy.
Educational only. Not medical advice. Concentration values are modeled estimates based on population pharmacokinetics, not predictions of individual blood levels.